GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tengion Inc (GREY:TNGNQ) » Definitions » Gross Margin %

Tengion (Tengion) Gross Margin % : 0.00% (As of Sep. 2014)


View and export this data going back to 2010. Start your Free Trial

What is Tengion Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Tengion's Gross Profit for the three months ended in Sep. 2014 was $0.00 Mil. Tengion's Revenue for the three months ended in Sep. 2014 was $0.00 Mil. Therefore, Tengion's Gross Margin % for the quarter that ended in Sep. 2014 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.


The historical rank and industry rank for Tengion's Gross Margin % or its related term are showing as below:


TNGNQ's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 60.91
* Ranked among companies with meaningful Gross Margin % only.

Tengion had a gross margin of N/A% for the quarter that ended in Sep. 2014 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Tengion was 0.00% per year.


Tengion Gross Margin % Historical Data

The historical data trend for Tengion's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tengion Gross Margin % Chart

Tengion Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
Gross Margin %
Get a 7-Day Free Trial - - - - -

Tengion Quarterly Data
Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Tengion's Gross Margin %

For the Biotechnology subindustry, Tengion's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tengion's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tengion's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Tengion's Gross Margin % falls into.



Tengion Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Tengion's Gross Margin for the fiscal year that ended in Dec. 2013 is calculated as

Gross Margin % (A: Dec. 2013 )=Gross Profit (A: Dec. 2013 ) / Revenue (A: Dec. 2013 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

Tengion's Gross Margin for the quarter that ended in Sep. 2014 is calculated as


Gross Margin % (Q: Sep. 2014 )=Gross Profit (Q: Sep. 2014 ) / Revenue (Q: Sep. 2014 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Tengion  (GREY:TNGNQ) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Tengion had a gross margin of N/A% for the quarter that ended in Sep. 2014 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Tengion Gross Margin % Related Terms

Thank you for viewing the detailed overview of Tengion's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Tengion (Tengion) Business Description

Traded in Other Exchanges
N/A
Address
3929 Westpoint Boulevard, Suite G, Winston-Salem, NC, USA, 27103
Tengion Inc is a regenerative medicine company. The company is engaged in discovering, manufacturing and commercializing neo-organs, or products composed of living cells, with or without synthetic or natural materials, implanted or injected into the body to engraft into, regenerate, or replace damaged tissue or organ. Its product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications. The company's solution Neo-Kidney Augment is based on its proprietary technology, which uses tubular epithelial cells, procured by a cortical biopsy of the patient's kidney, to create an injectable product candidate that can catalyze the regeneration of functional kidney tissue.
Executives
John L Miclot director, officer: President and CEO 5005 OLD ORCHARD LANE, GIBSONIA PA 15044
Lorin Randall director C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
A Brian Davis officer: Chf. Fin. Offr, VP Fin. C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Medtronic Inc 10 percent owner 710 MEDTRONIC PKWY, MINNEAPOLIS MN 55432
Johan Christenson 10 percent owner C/O ODLANDER, FREDRIKSON & CO. AB, STRANDVAGEN 5B, STOCKHOLM V7 SE-114 51
Staffan Lindstrand 10 percent owner C/O ODLANDER, FREDRIKSON & CO. AB, STRANDVAGEN 5B, STOCKHOLM V7 SE-114 51
Richard Kuntz director MEDTRONIC, INC., 710 MEDTRONIC PWKY MS LC 310, MINNEAPOLIS MN 55432
Diane Jorkasky director 60 MANOR AVENUE, WELLESLEY MA 02482
Mark Stejbach officer: VP and Chief Commercial Offcr C/O TENGION, INC., 2900 POTSHOP LANE, SUITE 100, EAST NORRITON PA 19403
Steven Nichtberger director, officer: President and CEO C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104
Johnson & Johnson 10 percent owner ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ 08933
Johnson & Johnson Innovation - Jjdc, Inc. 10 percent owner 410 GEORGE STREET, NEW BRUNSWICK NJ 08901
Oak Investment Partners Xi L P 10 percent owner 901 MAIN AVENUE, SUITE 600, NORWALK CT 06851

Tengion (Tengion) Headlines

From GuruFocus

Tengion Inc. Reports Operating Results (10-Q)

By gurufocus 10qk 05-20-2010